Skip to content

Efficacy of intravenous oliceridine on preventing sufentanil-­induced cough during general anaesthesia induction:A single-center, double-blind, randomized, controlled clinical trial.

Efficacy of intravenous oliceridine on preventing sufentanil-­induced cough during general anaesthesia induction:A single-center, double-blind, randomized, controlled clinical trial.

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099646
Enrollment
Unknown
Registered
2025-03-26
Start date
2025-03-31
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sufentanil-induced coughing

Interventions

OL group:OL Group Patients: 1.Oliceridine Administration: Administer 1.5 mg of oliceridine intravenously as an initial dose. 2.Sufentanil Administration: Within 15 seconds after the oliceridine inject
NS group:NS Group Patients: 1.Normal Saline Administration: Administer 1.5 mL of normal saline (0.9% sodium chloride solution) intravenously as an initial bolus. 2.Sufentanil Administration: Within 15

Sponsors

Department of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Age: 18 years <= participant age <= 70 years; 2.ASA Physical Status Classification: ASA I-III ; 3.Surgical Plan: Scheduled elective surgery requiring general anesthesia .

Exclusion criteria

Exclusion criteria: 1.severe hepatic and renal insufficiency; 2.chronic administration of opioids; 3.a history of respiratory diseases, such as asthma, chronic cough, chronic obstructive pulmonary disease (COPD),and upper respiratory tract infection within two weeks; 4.recently used bronchodilator; steroid therapy;angiotensin converting enzyme inhibitor(ACEI) or angiotensin receptor blocker(ARB); 5.allergy to Oliceridine; 6.predicted difficult airway.

Design outcomes

Primary

MeasureTime frame
Incidence of cough within 1 min after sufentanil injection;

Secondary

MeasureTime frame
Severity of cough;Hemodynamic changes during induction;

Countries

China

Contacts

Public ContactXiao Shi

Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

shixiao@renji.com+86 186 1697 0691

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026